SavedAdd your journal

Journals / Turkish Journal of Clinics and Laboratory / 2026 / Sayı: 1

Temporal trends in venous thromboembolism–related mortality among gastric cancer deaths in the United States, 1999–2020.

Amerika Birleşik Devletleri’nde gastrik kanserde venöz tromboembolizm ilişkili mortalitenin zaman içindeki değişimi, 1999–2020

Kadriye Başkurt(Etik Şehr Hastanesi)0000-0002-6091-730X
Galip Can Uyar(etlik şehir hastanesi)0000-0002-0698-777X
Enes Yeşilbaş(etlik şehir hastanesi)0000-0002-0947-702X
Hayriye Şahinli(etlik şehir hastanesi)0000-0002-1561-9346
Gökşen İnanç İmamoğlu(etlik şehir hastanesi)0000-0003-0356-0727
Pages
—
Publication Date
2026-03-29
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The proportion of gastric cancer deaths with VTE increased from 1.52% in 1999 to 2.90% in 2020, corresponding to an overall APC of 3.47% (95% CI, 3.00–3.95; p<0.001).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Venous thromboembolism (VTE) is a clinically important complication in gastric cancer, yet nationwide mortality trends remain poorly defined.
📊
Key Findings & Data:Materials and Methods: This population-based time-trend study used the CDC WONDER Multiple Cause of Death database (1999–2020).
💡
Conclusion & Impact:The proportion of gastric cancer deaths with VTE increased from 1.52% in 1999 to 2.90% in 2020, corresponding to an overall APC of 3.47% (95% CI, 3.00–3.95; p<0.001).
🔬Design:Modeling & Simulation
📍Scope:2020 Verileri
⚙️Variables:gastrik kanser · venöz tromboembolizm · kanser ilişkili tromboz

Abstract

Aim: Venous thromboembolism (VTE) is a clinically important complication in gastric cancer, yet nationwide mortality trends remain poorly defined. We evaluated temporal trends in VTE-related mortality among gastric cancer deaths in the United States. Materials and Methods: This population-based time-trend study used the CDC WONDER Multiple Cause of Death database (1999–2020). Gastric cancer deaths were identified using ICD-10 code C16, and VTE using codes I26 and I80–I82. Annual proportions of gastric cancer deaths with concomitant VTE were calculated. Temporal trends and annual percent change (APC) were assessed using linear and log-linear regression models with joinpoint analysis. Results: Among 254,449 gastric cancer deaths, 5,371 (2.11%) had concomitant VTE. The proportion of gastric cancer deaths with VTE increased from 1.52% in 1999 to 2.90% in 2020, corresponding to an overall APC of 3.47% (95% CI, 3.00–3.95; p<0.001). Joinpoint analysis identified a change-point in 2012, after which the upward trend accelerated (APC, 6.30%). Increasing trends were observed in both females and males and across all age groups, with no significant heterogeneity by sex or age. Conclusions: VTE-related mortality among gastric cancer deaths has risen steadily over the past two decades, highlighting the growing burden of cancer-associated thrombosis in gastric cancer.

Özet

Amaç: Venöz tromboembolizm (VTE), gastrik kanserde klinik açıdan önemli bir komplikasyon olmasına rağmen ülke düzeyindeki mortalite değişimleri yeterince tanımlanmamıştır. Bu çalışmada Amerika Birleşik Devletleri’nde gastrik kanser ölümleri arasında VTE ilişkili mortalitenin zaman içinde nasıl değiştiği değerlendirilmiştir. Gereç ve Yöntemler: Bu popülasyon temelli zaman eğilimi analizinde 1999–2020 yıllarını kapsayan CDC WONDER Çoklu Ölüm Nedeni veritabanı kullanıldı. Gastrik kanser ölümleri altta yatan ölüm nedeni olarak ICD-10 C16 kodu ile, VTE ise I26 ve I80–I82 kodları ile tanımlandı. Gastrik kanser ölümleri içinde eşlik eden VTE oranları hesaplandı. Zaman içindeki değişim doğrusal ve log-doğrusal regresyon modelleri ile değerlendirilerek yıllık yüzde değişim (APC) hesaplandı ve joinpoint analizi uygulandı. Bulgular: Toplam 254,449 gastrik kanser ölümü içinde 5,371 (%2,11) olguda eşlik eden VTE saptandı. Gastrik kanser ölümleri içinde VTE oranı 1999’da %1,52’den 2020’de %2,90’a yükseldi ve toplam APC %3,47 olarak bulundu (95% GA, %3,00–3,95; p<0,001). Joinpoint analizi 2012 yılında bir kırılma noktası olduğunu ve bu tarihten sonra artışın hızlandığını gösterdi (APC %6,30). Artış eğilimleri kadın ve erkeklerde ve tüm yaş gruplarında benzerdi; cinsiyet veya yaşa göre anlamlı heterojenite saptanmadı. Sonuç: Gastrik kanser ölümleri arasında VTE ilişkili mortalite son yirmi yılda belirgin şekilde artmıştır. Bu bulgular, gastrik kanserde kanser ilişkili tromboz yükünün giderek arttığını göstermektedir.

🔖

Cite This Article

Başkurt, K., Uyar, G. C., Yeşilbaş, E., Şahinli, H., İmamoğlu, G. İ. (2026). Temporal trends in venous thromboembolism–related mortality among gastric cancer deaths in the United States, 1999–2020.. Turkish Journal of Clinics and Laboratory, Sayı: 1. https://doi.org/10.18663/tjcl.1893840

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (20)

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-49.
  2. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet 2020; 396: 635-48.
  3. Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res 2010; 125: 490-93.
  4. Lyman GH, Culakova E, Poniewierski MS, Kuderer NM. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb Res 2018; 164: S112-S118.
  5. Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost 2017; 117: 219-30.
  6. Mulder FI, Horvath-Puho E, van Es N, van Laarhoven HWM, Pedersen L et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021; 137: 1959-69.
  7. Hisada Y, Mackman N. Mechanisms of cancer-associated thrombosis. Res Pract Thromb Haemost 2023; 7: 100123.
  8. Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood 2017; 130: 1499-506.
  9. Raskob GE, Angchaisuksiri P, Blanco AN, et al. Thrombosis: a major contributor to global disease burden. Thieme Medical Publishers 2014; 724-35.
  10. Lee KW, Bang SM, Kim S, Lee HJ, Shin DY et al. The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer. J Thromb Haemost 2010; 8: 540-47.
  11. Gervaso L, Dave H, Khorana AA. Venous and arterial thromboembolism in patients with cancer: JACC: CardioOncology state-of-the-art review. JACC CardioOncol 2021; 3: 173-90.
  12. Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers 2018; 10: 380.
  13. Mulder FI, Di Nisio M, Ay C, Carrier M, Bosch FTM et al. Clinical implications of incidental venous thromboembolism in cancer patients. Eur Respir J 2020; 55: 1901697.
  14. Dentali F, Ageno W, Becattini C, Galli L, Gianni M et al. Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res 2010; 125: 518-22.
  15. Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res 2006; 118: 555-68.
  16. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300: 2277-85.
  17. Key NS, Bohlke K, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update summary. J Oncol Pract 2019; 15: 661-64.
  18. Streiff MB, Holmstrom B, Angelini D, Ashrani A, Buckner T et al. Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2024; 22: 483-506.
  19. Adler-Milstein J, DesRoches CM, Kralovec P, Foster G, Worzala C et al. Electronic Health Record Adoption In US Hospitals: Progress Continues, But Challenges Persist. Health Aff (Millwood) 2015; 34: 2174-80.
  20. Darzi AJ, Repp AB, Spencer FA, Morsi RZ, Charide R et al. Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews. Blood Adv 2020; 4: 4929-44.